You are here



NorDiag has received the auditor's opinion of the Company's financial statements for 2011. The audit opinion contained a matter of emphasis. The Norwegian Share Trading Act prescribes that NorDiag announces such point of emphasis in a notice to the market.

In the matter of emphasis, the auditor makes references to the going concern section in the report from the Board of Directors and to notes 3, 21 and 27 in the financial statements which outlines the material uncertainty related to the process of securing additional funds to enable NorDiag to continue its operation through 2012. These conditions indicate the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern.

The Board of directors of NorDiag takes for its basis that the Company will obtain adequate funding in 2012, and the financial statements has been prepared on the basis of going concern.

Auditors report enclosed.

For further information, please contact:
 CEO Mårten Wigstøl, Phone: +47 911 65775
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNAfrom difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 29.15 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
For further information -
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)


Read the notice in Norwegian here.